Tscan therapeutics announces upcoming presentations at the american society of gene and cell therapy 27th annual meeting

Waltham, mass., april 22, 2024 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced the acceptance of one abstract for oral presentation and four abstracts for poster presentation at the upcoming american society of gene and cell therapy (asgct) 27th annual meeting being held may 7-11 in baltimore, md as well as virtually.
TCRX Ratings Summary
TCRX Quant Ranking